Literature DB >> 19319851

Physiological roles of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.

Takayuki Sugiura1.   

Abstract

2-Arachidonoylglycerol is an arachidonic acid-containing monoacylglycerol isolated from the rat brain and canine gut as an endogenous ligand for the cannabinoid receptors (CB1 and CB2). 2-Arachidonoylglycerol binds to both the CB1 receptor, abundantly expressed in the nervous system, and the CB2 receptor, mainly expressed in the immune system, with high affinity, and exhibits a variety of cannabimimetic activities. Notably, anandamide, another endogenous ligand for the cannabinoid receptors, acts as a partial agonist at these cannabinoid receptors, whereas 2-arachidonoylglycerol acts as a full agonist. The results of structure-activity relationship experiments strongly suggested that 2-arachidonoylglycerol rather than anandamide is the true natural ligand for both the CB1 and the CB2 receptors. Evidence is gradually accumulating which shows that 2-arachidonoylglycerol plays physiologically and pathophysiologically essential roles in various mammalian tissues and cells. (c) 2009 International Union of Biochemistry and Molecular Biology, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19319851     DOI: 10.1002/biof.18

Source DB:  PubMed          Journal:  Biofactors        ISSN: 0951-6433            Impact factor:   6.113


  17 in total

Review 1.  Minireview: From the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulation.

Authors:  Robert P Picone; Debra A Kendall
Journal:  Mol Endocrinol       Date:  2015-04-13

2.  Pharmacological tools to mobilise mesenchymal stromal cells into the blood promote bone formation after surgery.

Authors:  Tariq G Fellous; Andia N Redpath; Mackenzie M Fleischer; Sapan Gandhi; Samantha E Hartner; Michael D Newton; Moïra François; Suet-Ping Wong; Kate H C Gowers; Adam M Fahs; Daniel R Possley; Dominique Bonnet; Paula Urquhart; Anna Nicolaou; Kevin C Baker; Sara M Rankin
Journal:  NPJ Regen Med       Date:  2020-02-21

Review 3.  Cannabinoid receptors: nomenclature and pharmacological principles.

Authors:  Linda Console-Bram; Jahan Marcu; Mary E Abood
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-02-28       Impact factor: 5.067

4.  Endocannabinoids produced upon action potential firing evoke a Cl(-) current via type-2 cannabinoid receptors in the medial prefrontal cortex.

Authors:  Femke S den Boon; Pascal Chameau; Kas Houthuijs; Simone Bolijn; Nicolina Mastrangelo; Chris G Kruse; Mauro Maccarrone; Wytse J Wadman; Taco R Werkman
Journal:  Pflugers Arch       Date:  2014-03-28       Impact factor: 3.657

5.  Synaptic and cognitive improvements by inhibition of 2-AG metabolism are through upregulation of microRNA-188-3p in a mouse model of Alzheimer's disease.

Authors:  Jian Zhang; Mei Hu; Zhaoqian Teng; Ya-Ping Tang; Chu Chen
Journal:  J Neurosci       Date:  2014-11-05       Impact factor: 6.167

6.  Identification by nuclear magnetic resonance spectroscopy of an active-site hydrogen-bond network in human monoacylglycerol lipase (hMGL): implications for hMGL dynamics, pharmacological inhibition, and catalytic mechanism.

Authors:  Ioannis Karageorgos; Sergiy Tyukhtenko; Nikolai Zvonok; David R Janero; Christine Sallum; Alexandros Makriyannis
Journal:  Mol Biosyst       Date:  2010-05-12

Review 7.  Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.

Authors:  Ryan Wyrofsky; Paul McGonigle; Elisabeth J Van Bockstaele
Journal:  Expert Opin Drug Discov       Date:  2014-12-09       Impact factor: 6.098

8.  Endocannabinoid signaling in neurotoxicity and neuroprotection.

Authors:  C Pope; R Mechoulam; L Parsons
Journal:  Neurotoxicology       Date:  2009-12-05       Impact factor: 4.294

9.  Reduction in endocannabinoid tone is a homeostatic mechanism for specific inhibitory synapses.

Authors:  Jimok Kim; Bradley E Alger
Journal:  Nat Neurosci       Date:  2010-03-28       Impact factor: 24.884

10.  The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells.

Authors:  Kevin Wilhelmsen; Samira Khakpour; Alphonso Tran; Kayla Sheehan; Mark Schumacher; Fengyun Xu; Judith Hellman
Journal:  J Biol Chem       Date:  2014-03-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.